ER-Positive Metastatic Breast Cancer — An Interview with Prof Patrick Neven on the Role of Oral Selective Estrogen Receptor Degraders (Companion Faculty Lecture)
Update: 2025-11-03
Description
Featuring a slide presentation and related discussion from Prof Patrick Neven, including the following topics:
- Biology of the estrogen receptor (ER) and mechanisms of resistance to therapy (0:00 )
- Clinical trial data involving oral selective ER degraders (SERDs) for endocrine-resistant ER-positive, HER2-negative metastatic breast cancer (13:34 )
- Utility of switching to an oral SERD before radiographic disease progression for patients receiving first-line endocrine treatment (23:12 )
- Ongoing trials with oral SERDs for ER-positive, HER2-negative breast cancer (27:13 )
- Case: Patient with ER-positive, HER2-negative breast cancer receives imlunestrant upon disease progression on first-line letrozole (32:34 )
- Case: Patient with ER-positive, HER2-negative breast cancer receives imlunestrant/abemaciclib upon relapse on letrozole/abemaciclib (34:16 )
- Case: Patient with ER-positive, HER2-negative breast cancer receives camizestrant after first-line tamoxifen (36:20 )
- Case: Patient with ER-positive, HER2-negative breast cancer receives elacestrant after disease progression on first-line letrozole/palbociclib (38:11 )
Comments
In Channel
Download from Google Play
Download from App Store
United States00:00
00:00
x
